# Prevention of Contrast Induced Nephropathy by Erythropoietin

Study · id `cardio:ct-nct01364402` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01364402](<https://clinicaltrials.gov/study/NCT01364402>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01364402

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 142 participants.

## Technical summary

Registry record NCT01364402. Randomized; quadruple masking; primary purpose prevention. Start 2011-08 (registry gives no type); primary completion 2013-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 142 participants (planned count; ClinicalTrials.gov record NCT01364402, source copy `cardio:ctgov-nct01364402-2012-10-10`, retrieved 2026-10-26)
- Start date: 2011-08 (registry gives no type) (ClinicalTrials.gov record NCT01364402, source copy `cardio:ctgov-nct01364402-2012-10-10`, retrieved 2026-10-26)
- Primary completion: 2013-08 (anticipated) (ClinicalTrials.gov record NCT01364402, source copy `cardio:ctgov-nct01364402-2012-10-10`, retrieved 2026-10-26)
- Completion: 2013-12 (anticipated) (ClinicalTrials.gov record NCT01364402, source copy `cardio:ctgov-nct01364402-2012-10-10`, retrieved 2026-10-26)
- Countries: Israel (ClinicalTrials.gov record NCT01364402, source copy `cardio:ctgov-nct01364402-2012-10-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01364402-2012-10-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Prevention of Contrast Induced Nephropathy by Erythropoietin
- Condition: Diabetes
- Condition: Chronic Kidney Insufficiency
- Intervention (Drug): Epoetin beta
- Intervention (Drug): Saline 0.9%
- Lead sponsor: Western Galilee Hospital-Nahariya
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: d8e6aa12ca26a0d4d73979603551ed262d1ca8dcfea7062d94511da01fb3ac01
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
